News

Pacira to Report 2024 Financial Results on Thursday February 27, 2025

PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to…

10 months ago

Conduit Progresses Phase II of its AI Initiative with Sarborg

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug…

10 months ago

ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables

Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN…

10 months ago

Bonus Biogroup Announces U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for MesenCure™ Phase III Clinical Study in Respiratory Distress

The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute…

10 months ago

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

Ongoing Phase 1 study is funded by a foundation grant Daré received a royalty-free, exclusive license to the US patents…

10 months ago

Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission

WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced an exclusive in-license…

10 months ago

Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program’s Success and Growth Potential

OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®PHOENIX, Feb. 20, 2025…

10 months ago

T-knife Therapeutics Welcomes Dr. Sophie Papa to its Board of Directors

SAN FRANCISCO and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor…

10 months ago

Better Choice Company Agrees in Principle to Licensing Agreement in Asia for its Halo Elevate® Brand

Better Choice will receive a 5.5% royalty on all sales of the Halo Elevate Brand in this regionTAMPA, Fla., Feb.…

10 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…

10 months ago